Abstract
Dopamine agonists (DA) are a first-line therapy for prolactinomas (PA). However, nearly 10% of prolactinomas do not respond to DA therapy. A considerable number of studies have shown that estrogen plays an important role in the development of prolactinomas. However, the expression of estrogen receptors (ER) in prolactinomas has not been fully explored. Accordingly, we examined the levels of ESR1 and its subtypes Δ5-Del-ESR1 and ESR2 mRNA in prolactinomas. In the present study, we found that ESR1 mRNA levels were significantly lower in women of childbearing age group compared to men (P
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
